X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Presented in vivo efficacy data for its small molecule therapy engineered via ALEMBIC™ drug discovery platform, targetes senescent cells that drive cellular aging to treat dermatological diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2023
Details:
The funding will support research and development of a pharmacological regenerative treatment of idiopathic pulmonary fibrosis (IPF), RBO-0618, targeting senescent lung stem cells.
Lead Product(s): RBO-0618
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RBO-0618
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: California Institute for Regenerative Medicine
Deal Size: $1.4 million Upfront Cash: Undisclosed
Deal Type: Funding February 06, 2023
Details:
The funding will be used to advance the company’s lead candidates in respiratory diseases with significant unmet medical need, such as idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).
Lead Product(s): Undisclosed
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: Khosla Ventures
Deal Size: $12.0 million Upfront Cash: Undisclosed
Deal Type: Financing December 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
